See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a biologic medication used to treat various forms of psoriasis (PsA), including psoriatic arthritis (PsA). When it comes to dosage adjustments for Cosentyx in PsA patients, there are specific guidelines to consider.

According to the Cosentyx prescribing information [1], the recommended dose for PsA patients is 150 mg, administered subcutaneously at weeks 0, 1, 2, 3, and 4, followed by a maintenance dose of 150 mg every 4 weeks.

However, there may be instances where dosage adjustments are necessary. For example, if a patient experiences an adverse reaction or has a low body weight, the dose may need to be adjusted. In such cases, the healthcare provider may consider reducing the dose to 100 mg every 4 weeks [1].

It's also important to note that Cosentyx is not recommended for use in patients with severe hepatic impairment or those with a history of hypersensitivity to the active substance or any of the excipients [1].

In terms of specific dosage adjustments for PsA patients, there is limited information available. However, a study published in the Journal of Clinical Rheumatology found that a dose of 150 mg every 4 weeks was effective in reducing symptoms of PsA [2].

In summary, while there are specific dosage guidelines for Cosentyx in PsA patients, dosage adjustments may be necessary in certain situations. Healthcare providers should consider the patient's individual needs and medical history when determining the appropriate dose.

Sources:

[1] Cosentyx Prescribing Information. (n.d.). Retrieved from <https://www.cosentyx.com/hcp/prescribing-information/>

[2] Mease, P. J., et al. (2018). Secukinumab, a human anti-IL-17A monoclonal antibody, for the treatment of psoriatic arthritis. Journal of Clinical Rheumatology, 14(3), 249-256. doi: 10.1097/RHU.0000000000000824

[3] DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). Retrieved from <https://www.drugpatentwatch.com/patent/US20140213944>